Abstract
To investigated the molecular epidemiology and in vitro antifungal susceptibility of Cryptococcus isolates from West China Hospital from HIV and non-HIV patients between 2009 and 2015. A total of 132 C. neoformans and C. gattii were subjected to antifungal susceptibility testing by E-test method. Among the 132 isolates, 42 C. neoformans and C. gattii were analyzed by mating type and URA5-RFLP. A total of 113 C. neoformans and C. gattii were subjected to multi-locus sequence typing (MLST). MLST results revealed that ST5 was the major molecular type. The wild-type (WT) phenotype was seen in 91.5–100% of C. neoformans isolates for amphotericin B, 5-flucytosine, fluconazole, and voriconazole. However, 72.3% (94/130) of C. neoformans isolates were non-wild-type (non-WT) to itraconazole by E-test method. In the sixth study year, the geometric mean, MIC50 and MIC90 of fluconazole were the highest (P < 0.001). Among 132 patients. 52 were coinfected with HIV and 80 were HIV-negative. Isolates from HIV and non-HIV patients showed no differences in susceptibility to amphotericin B (P = 0.544), 5-flucytosine (P = 0.063), fluconazole (P = 0.570), voriconazole (P = 0.542), and itraconazole (P = 0.787). Our study showed that Cryptococcus in southwest China showed a low degree of genetic diversity. The increased MIC values of fluconazole are noted. Cryptococcus isolates from HIV and non-HIV patients have shown no differences in susceptibility to five antifungal agents.
Similar content being viewed by others
References
Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware DR (2017) Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis 17(8):873–881. https://doi.org/10.1016/s1473-3099(17)30243-8
Makadzange AT, McHugh G (2014) New approaches to the diagnosis and treatment of cryptococcal meningitis. Semin Neurol 34(1):47–60. https://doi.org/10.1055/s-0034-1372342
Dou HT, Xu YC, Wang HZ, Li TS (2015) Molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii in China between 2007 and 2013 using multilocus sequence typing and the DiversiLab system. Eur J Clin Microbiol Infect Dis 34(4):753–762. https://doi.org/10.1007/s10096-014-2289-2
Espinel-Ingroff A, Kidd SE (2015) Current trends in the prevalence of Cryptococcus gattii in the United States and Canada. Infect Drug Resist 8:89–97. https://doi.org/10.2147/idr.S57686
Cogliati M (2013) Global molecularepidemiology of Cryptococcus neoformans and Cryptococcus gattii: an atlas of the molecular types. Scientifica (Cairo) 2013:675213. https://doi.org/10.1155/2013/675213
Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, Esposto MC, Fisher M, Gilgado F, Hagen F, Kaocharoen S, Litvintseva AP, Mitchell TG, Simwami SP, Trilles L, Viviani MA, Kwon-Chung J (2009) Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 47(6):561–570. https://doi.org/10.1080/13693780902953886
Hagen F, Khayhan K, Theelen B, Kolecka A, Polacheck I, Sionov E, Falk R, Parnmen S, Lumbsch HT, Boekhout T (2015) Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol 78:16–48. https://doi.org/10.1016/j.fgb.2015.02.009
Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 50(3):291–322. https://doi.org/10.1086/649858
Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, Kamwendo D, van der Horst CM, Harrison TS (2010) Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 50(3):338–344. https://doi.org/10.1086/649861
Muzoora CK, Kabanda T, Ortu G, Ssentamu J, Hearn P, Mwesigye J, Longley N, Jarvis JN, Jaffar S, Harrison TS (2012) Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect 64(1):76–81. https://doi.org/10.1016/j.jinf.2011.10.014
Chong HS, Dagg R, Malik R, Chen SR, Carter D (2010) In vitro susceptibility of the yeast pathogen Cryptococcus to fluconazole and other azoles varies with molecular genotype. J Clin Microbiol 48(11):4115–4120. https://doi.org/10.1128/jcm.01271-10
Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Florl C, Lockhart SR, Martins MA, Meis JF, Melhem MSC, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J (2012) Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 56(11):5898–5906. https://doi.org/10.1128/aac.01115-12
Chen JH, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ (2008) Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 14(5):755–762. https://doi.org/10.3201/eid1405.071312
Feng XB, Yao ZR, Ren DM, Liao WQ, Wu JS (2008) Genotype and mating type analysis of Cryptococcus neoformans and Cryptococcus gattii isolates from China that mainly originated from non-HIV-infected patients. FEMS Yeast Res 8(6):930–938. https://doi.org/10.1111/j.1567-1364.2008.00422.x
Liu Y, Kang M, Wu SY, Ma Y, Chen ZX, Xie Y, Tang JT (2017) Different characteristics of cryptococcal meningitis between HIV-infected and HIV-uninfected patients in the southwest of China. Med Mycol 55(3):255–261. https://doi.org/10.1093/mmy/myw075
Xiao M, Chen SCA, Kong FR, Fan X, Cheng JW, Hou X, Zhou ML, Wang H, Xu YC, China Hosp Invasive Fungal S (2018) Five-year China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study of invasive fungal infections caused by noncandidal yeasts: species distribution and azole susceptibility. Infect Drug Resist 11:1659–1667. https://doi.org/10.2147/idr.S173805
Wu SY, Lei Y, Kang M, Xiao YL, Chen ZX (2015) Molecular characterisation of clinical Cryptococcus neoformans and Cryptococcus gattii isolates from Sichuan province, China. Mycoses 58(5):280–287. https://doi.org/10.1111/myc.12312
Zhu H, Qu F, Zhu LH (1993) Isolation of genomic DNAs from plants, fungi and bacteria using benzyl chloride. Nucleic Acids Res 21(22):5279–5280. https://doi.org/10.1093/nar/21.22.5279
Chaturvedi S, Rodeghier B, Fan JJ, McClelland CM, Wickes BL, Chaturvedi V (2000) Direct PCR of Cryptococcus neoformans MAT alpha and MATa pheromones to determine mating type, ploidy, and variety: a tool for epidemiological and molecular pathogenesis studies. J Clin Microbiol 38(5):2007–2009. https://doi.org/10.1128/jcm.38.5.2007-2009.2000
Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E, IberoAmerican Cryptococcal S (2003) Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9(2):189–195. https://doi.org/10.3201/eid0902.020246
Clinical and Laboratory Standards Institute (2018) CLSI document M59. Epidemiological cutoff values for antifungal susceptibility testing, 2nd edn. CLSI, Wayne
Kwon-Chung KJ, Fraser JA, Doering TL, Wang ZA, Janbon G, Idnurm A, Bahn YS (2014) Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med 4(7). https://doi.org/10.1101/cshperspect.a019760
Park SH, Choi SC, Lee KW, Kim MN, Hwang SM (2015) Genotypes of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Korea. Mycobiology 43(3):360–365. https://doi.org/10.5941/myco.2015.43.3.360
Worasilchai N, Tangwattanachuleeporn M, Meesilpavikkai K, Folba C, Kangogo M, Gross U, Weig M, Bader O, Chindamporn A (2017) Diversity and antifungal drug susceptibility of Cryptococcus isolates in Thailand. Med Mycol 55(6):680–685. https://doi.org/10.1093/mmy/myw130
Khayhan K, Hagen F, Pan WH, Simwami S, Fisher MC, Wahyuningsih R, Chakrabarti A, Chowdhary A, Ikeda R, Taj-Aldeen SJ, Khan Z, Ip M, Imran D, Sjam R, Sriburee P, Liao WQ, Chaicumpar K, Vuddhakul V, Meyer W, Trilles L, van Iersel LJJ, Meis JF, Klaassen CHW, Boekhout T (2013) Geographically structured populations of Cryptococcus neoformans variety grubii in Asia correlate with HIV status and show a clonal population structure. PLoS One 8(9). https://doi.org/10.1371/journal.pone.0072222
Day JN, Qihui S, Thanh LT, Trieu PH, Van AD, Thu NH, Chau TTH, Lan NPH, Chau NVV, Ashton PM, Thwaites GE, Boni MF, Wolbers M, Nagarajan N, Tan PBO, Baker S (2017) Comparative genomics of Cryptococcus neoformans var. grubii associated with meningitis in HIV infected and uninfected patients in Vietnam. PLoS Negl Trop Dis 11(6). https://doi.org/10.1371/journal.pntd.0005628
Chen SCA, Meyer W, Sorrell TC (2014) Cryptococcus gattii infections. Clin Microbiol Rev 27(4):980–1024. https://doi.org/10.1128/cmr.00126-13
Fan X, Xiao M, Chen S, Kong F, Dou HT, Wang H, Xiao YL, Kang M, Sun ZY, Hu ZD, Wan Z, Chen SL, Liao K, Chu YZ, Hu TS, Zou GL, Hou X, Zhang L, Zhao YP, Xu YC, Liu ZY (2016) Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China. Clin Microbiol Infect 22(10). https://doi.org/10.1016/j.cmi.2016.07.008
Hagen F, Colom MF, Swinne D, Tintelnot K, Latta R, Montagna MT, Torres-Rodriguez JM, Cogliati M, Velegraki A, Burggraaf A, Kamermans A, Sweere JM, Meis JF, Klaassen CHW, Boekhout T (2012) Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg Infect Dis 18(10):1618–1624. https://doi.org/10.3201/eid1810.120068
Herkert PF, Meis JF, Salvador GLO, Gomes RR, Vicente VA, Muro MD, Pinheiro RL, Colombo AL, Schwarzbold AV, Oliveira CS, Ferreira MS, Queiroz-Telles F, Hagen F (2018) Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil. J Med Microbiol 67(4):560–569. https://doi.org/10.1099/jmm.0.000698
Lee GHA, Arthur I, Merritt A, Leung M (2019) Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility. Med Mycol 57(8):1004–1010. https://doi.org/10.1093/mmy/myy161
Smith KD, Achan B, Hullsiek KH, McDonald TR, Okagaki LH, Alhadab AA, Akampurira A, Rhein JR, Meya DB, Boulware DR, Nielsen K, Team A-CC (2015) Increased antifungal drug resistance in clinical isolates of Cryptococcus neoformans in Uganda. Antimicrob Agents Chemother 59(12):7197–7204. https://doi.org/10.1128/aac.01299-15
Chen YC, Chang TY, Liu JW, Chen FJ, Chien CC, Lee CH, Lu CH (2015) Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study. BMC Infect Dis 15(1). https://doi.org/10.1186/s12879-015-1023-8
Nascimento E, Vitali LH, Kress MRV, Martinez R (2017) Cryptococcus neoformans and C gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease. Rev Inst Med Trop Sao Paulo 59. https://doi.org/10.1590/s1678-9946201759049
Lockhart SR, Iqbal N, Bolden CB, DeBess EE, Marsden-Haug N, Worhle R, Thakur R, Harris JR, Cryptococcus Gattii PNWP (2012) Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis 73(2):144–148. https://doi.org/10.1016/j.diagmicrobio.2012.02.018
Li M, Liao Y, Chen M, Pan WH, Weng LX (2012) Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China. Braz J Infect Dis 16(2):175–179. https://doi.org/10.1590/s1413-86702012000200012
Arsenijevic VA, Pekmezovic MG, Meis JF, Hagen F (2014) Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates. Mycoses 57(6):380–387. https://doi.org/10.1111/myc.12171
Pan WH, Khayhan K, Hagen F, Wahyuningsih R, Chakrabarti A, Chowdhary A, Ikeda R, Taj-Aldeen SJ, Khan Z, Imran D, Sjam R, Sriburee P, Liao WQ, Chaicumpar K, Ingviya N, Mouton JW, Curfs-Breuker I, Boekhout T, Meis JF, Klaassen CHW (2012) Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes. PLoS One 7(3). https://doi.org/10.1371/journal.pone.0032868
Acknowledgments
We thank Prof. Liao Wanqing and Dr. Chen Min (Department of Dermatology, Changzheng Hospital, Second Military University, Shanghai) for providing the reference strains.
Funding
This work was supported by the SCI fund of West China Hospital, Sichuan University.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Ethical approval was given by West China Hospital, Sichuan University Biomedical Ethics Committee with the following approval number: 53(2018).
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wu, SY., Kang, M., Liu, Y. et al. Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China. Eur J Clin Microbiol Infect Dis 40, 287–295 (2021). https://doi.org/10.1007/s10096-020-04013-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-020-04013-4